Evercore ISI lowered the firm’s price target on Bio-Techne (TECH) to $68 from $72 and keeps an Outperform rating on the shares. The firm said it is trimming expectations for organic growth due to timing issue with cell therapy customers, yet the macro recovery thesis remains intact.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne price target raised to $70 from $65 at UBS
- Bio-Techne price target lowered to $61 from $62 at Baird
- Bio-Techne Reports Q1 FY2026 Earnings with Strategic Focus
- Bio-Techne’s Earnings Call: Mixed Sentiment Amid Growth and Challenges
- Positive Long-Term Outlook for Bio-Techne Amid Short-Term Challenges